LCN2 and acute kidney injury: The first-generation AKI biomarkers, such as damage markers like neutrophil gelatinase-associated lipocalin (NGAL) and L-type fatty acid-binding proteins (L-FABP), have been developed over the past 20 years, but they have limitations in specificity and sensitivity, particularly in patients with comorbid conditions [1].